Tocilizumab is an anti-interleukin-6 receptor (IL-6R) monoclonal antibody, currently approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and rheumatoid arthritis.
MoreTrastuzumab, an anti- ERBB2 (HER2 or HER-2/neu) humanized monoclonal antibody, is used to treat “HER2-positive” tumors.
MorePembrolizumab (MK-3475, lambrolizumab), a highly selective humanized monoclonal immunoglobulin G4 (IgG4)/kappa isotype antibody that blocks the interaction between PD-1 and its ligands, has demonstrated antitumor activity in multiple tumor types.
MoreNivolumab (BMS-936558, MDX-1106, ONO-4538), an anti-PD-1 monoclonal antibody, has been reported to have anti- tumor effects and approved for the treatment of unresectable or metastatic melanoma in treatment-refractory patients.
MoreObinutuzumab (Gazyva) is a unique, third-generation, fully humanized glycoengineered IgG1 type II anti-CD20 monoclonal antibody monoclonal antibody, approved in chronic lymphocytic leukemia (B-CLL) and follicular lymphoma (FL).
More